NAS
KNSA icon

Nykredit A/S’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Nykredit A/S’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.9K Buy
+530
New +$27.5K ﹤0.01% 1585

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Nykredit A/S's KNSA Position: Q2 2026 in Review

Nykredit A/S opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 530 shares worth $33.9K. The stake represents ﹤0.01% of the portfolio and ranks #1585 among its holdings.

191 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Nykredit A/S held 530 shares of Kiniksa Pharmaceuticals worth $33.9K as of Q2 2026.
  • Kiniksa Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1585 holding.
  • 191 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.